Nisin A Treatment to Protect Honey Bee Larvae from European Foulbrood Disease.

European foulbrood (EFB) is a bee larvae-specific infectious disease and the causative pathogen is Melissococcus plutonius. Broad-spectrum antibiotics have classically been used in many countries to control the pathogens; however, their use in apiaries was discontinued in several countries due to concerns regarding the health of bees and humans. Therefore, the development of alternative treatments for use in apiaries that are safe for bees and humans is essential.

The first isolation of Clostridium massiliodielmoense from a dead beef cow in Japan and pitfalls to be aware of in identifying the Clostridium species.

Clostridium sp. was detected in the organs of a cow with black watery diarrhea in Japan. Results identifying this species were inconsistent; Clostridium novyi type A infection was suggested by PCR assay targeting Clostridium fliC region (fliC-multiplex PCR), while 16S rRNA gene sequencing identified the isolated bacteria as Clostridium massiliodielmoense.

Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y.

In papillary renal neoplasm with reverse polarity (PRNRP), the status of chromosomal copy number alterations, especially chromosomes 7/17 gain and chromosome Y loss, has remained controversial. In the literatures, there is a discrepancy among the results of chromosomal alteration in PRNRP depending on the analytical methods. Here, we comprehensively analyzed the status of chromosomal abnormalities in PRNRP.

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.

Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual HLA genotypes on the efficacy of an anti-PD-1 Ab, nivolumab, in treating advanced RCC. Patient enrollment was conducted across 23 institutions in Japan from August 19, 2019, to September 30, 2020, with follow-up concluding on March 31, 2021.